StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )
A Multicenter, Open-label, Study of StrataGraft® Skin Tissue in Adult Subjects With Deep Partial-Thickness Thermal Burns
Sponsor: Stratatech, a Mallinckrodt Company
This PHASE3 trial investigates Deep Partial-thickness Burn and is currently completed. Stratatech, a Mallinckrodt Company leads this study, which shows 14 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Approved For Marketing → Completed · Phase: None → PHASE3
-
Nov 2021 — Dec 2023 [monthly]
Approved For Marketing
Status: Available → Approved For Marketing
▶ Show 9 earlier versions
-
Oct 2021 — Nov 2021 [monthly]
Available
-
Sep 2021 — Oct 2021 [monthly]
Available
-
Apr 2021 — Sep 2021 [monthly]
Available
-
Jan 2021 — Apr 2021 [monthly]
Available
-
Jun 2020 — Jan 2021 [monthly]
Available
-
Apr 2020 — Jun 2020 [monthly]
Available
-
Feb 2020 — Apr 2020 [monthly]
Available
-
Jan 2020 — Feb 2020 [monthly]
Available
Status: Temporarily Not Available → Available
-
Nov 2019 — Jan 2020 [monthly]
Temporarily Not Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Stratatech, a Mallinckrodt Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Baton Rouge, United States
- • Columbia, United States
- • Gainesville, United States
- • Iowa City, United States
- • Madison, United States
- • New Orleans, United States
- • Orange, United States
- • Pittsburgh, United States
- • Washington D.C., United States
- • Winston-Salem, United States